Gene Biotherapeutics Inc (CRXM)

0.00 USD  |  OTCM  |  Apr 24, 16:00
More

Price Chart

Key Stats

View All Stats
Price and Performance
Market Cap 0.00
52 Week High (Daily) Upgrade
52 Week Low (Daily) Upgrade
All-Time High (Daily) Upgrade
Year to Date Total Returns (Daily) Upgrade
1 Month Total Returns (Daily) Upgrade
1 Year Total Returns (Daily) --
Valuation
PE Ratio --
PE Ratio (Forward) Upgrade
PS Ratio --
Price to Book Value --
EV to EBITDA Upgrade
Dividend
Dividend --
Dividend Yield (Forward) Upgrade
Financials
Revenue (5 Year Growth) Upgrade
Revenue (Quarterly YoY Growth) Upgrade
EPS Diluted (5 Year Growth) Upgrade
EPS Diluted (Quarterly YoY Growth) Upgrade
Debt to Equity Ratio --
Return on Equity Upgrade
Return on Assets Upgrade
Risk
Beta (5Y) Upgrade
Max Drawdown (5Y) 100.00%

Ratings

Y-Rating Upgrade
Value Score Upgrade
Fundamental Score Upgrade
Valuation (Hist. Mult.) Upgrade

Profile

Gene Biotherapeutics Inc is a clinical stage biotechnology company focused on pre-clinical, clinical, and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The company's lead product candidate Generx is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.
URL https://www.genebiotherapeutics.com
Investor Relations URL N/A
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release N/A
Last Earnings Release Jun. 12, 2014
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ratings

Y-Rating Upgrade
Value Score Upgrade
Fundamental Score Upgrade
Valuation (Hist. Mult.) Upgrade

Profile

Gene Biotherapeutics Inc is a clinical stage biotechnology company focused on pre-clinical, clinical, and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The company's lead product candidate Generx is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.
URL https://www.genebiotherapeutics.com
Investor Relations URL N/A
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release N/A
Last Earnings Release Jun. 12, 2014
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A